Evidence map›Paper›PMID 39112663›Full record

ArticleCellular and molecular life sciences : CMLS2024

Neuroprotection by ADAM10 inhibition requires TrkB signaling in the Huntington's disease hippocampus.

Andrea Scolz, Elena Vezzoli, Michela Villa, Francesca Talpo, Jessica Cazzola, Francesca Raffin, Chiara Cordiglieri, Andrea Falqui, Giuseppe Pepe, Vittorio Maglione and 3 more

Abstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Andrea ScolzDepartment of Biosciences, University of Milan, Milan, Italy.
Elena VezzoliDepartment of Biosciences, University of Milan, Milan, Italy.
Michela VillaDepartment of Biosciences, University of Milan, Milan, Italy.
Francesca TalpoDepartment of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, Pavia, Italy.
Jessica CazzolaDepartment of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, Pavia, Italy.
Francesca RaffinDepartment of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, Pavia, Italy.
Chiara CordiglieriIstituto Nazionale di Genetica Molecolare "Romeo ed Enrica Invernizzi", Milan, Italy.
Andrea FalquiInterdisciplinary Centre for Nanostructured Materials and Interfaces (CIMaINa), Department of Physics, University of Milan, Milan, Italy.
Giuseppe PepeIRCCS Neuromed, Pozzilli, Isernia, Italy.
Vittorio MaglioneIRCCS Neuromed, Pozzilli, Isernia, Italy.
Dario BesussoDepartment of Biosciences, University of Milan, Milan, Italy.
Gerardo BiellaDepartment of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, Pavia, Italy.
Chiara ZuccatoDepartment of Biosciences, University of Milan, Milan, Italy. chiara.zuccato@unimi.it.ORCID http://orcid.org/0000-0003-1771-3392

Funding

Fondazione Telethon GGP13053Fondazione Telethon GGP20067Fondazione Telethon GGP20101Ministero dell'Istruzione, dell'Università e della Ricerca 20128XWKTX
6 · The paper itself

Abstract

Synaptic dysfunction is an early pathogenic event leading to cognitive decline in Huntington's disease (HD). We previously reported that the active ADAM10 level is increased in the HD cortex and striatum, causing excessive proteolysis of the synaptic cell adhesion protein N-Cadherin. Conversely, ADAM10 inhibition is neuroprotective and prevents cognitive decline in HD mice. Although the breakdown of cortico-striatal connection has been historically linked to cognitive deterioration in HD, dendritic spine loss and long-term potentiation (LTP) defects identified in the HD hippocampus are also thought to contribute to the cognitive symptoms of the disease. The aim of this study is to investigate the contribution of ADAM10 to spine pathology and LTP defects of the HD hippocampus. We provide evidence that active ADAM10 is increased in the hippocampus of two mouse models of HD, leading to extensive proteolysis of N-Cadherin, which has a widely recognized role in spine morphology and synaptic plasticity. Importantly, the conditional heterozygous deletion of ADAM10 in the forebrain of HD mice resulted in the recovery of spine loss and ultrastructural synaptic defects in CA1 pyramidal neurons. Meanwhile, normalization of the active ADAM10 level increased the pool of synaptic BDNF protein and activated ERK neuroprotective signaling in the HD hippocampus. We also show that the ADAM10 inhibitor GI254023X restored LTP defects and increased the density of mushroom spines enriched with GluA1-AMPA receptors in HD hippocampal neurons. Notably, we report that administration of the TrkB antagonist ANA12 to HD hippocampal neurons reduced the beneficial effect of GI254023X, indicating that the BDNF receptor TrkB contributes to mediate the neuroprotective activity exerted by ADAM10 inhibition in HD. Collectively, these findings indicate that ADAM10 inhibition coupled with TrkB signaling represents an efficacious strategy to prevent hippocampal synaptic plasticity defects and cognitive dysfunction in HD.

Indexed as

ADAM10 ProteinAmyloid Precursor Protein SecretasesHippocampusHuntington DiseaseLong-Term PotentiationMembrane ProteinsReceptor, trkBSignal TransductionAnimalsBrain-Derived Neurotrophic FactorCadherinsDendritic SpinesDisease Models, AnimalMaleMiceMice, Inbred C57BLADAM10 ProteinAdam10 protein, mouseAmyloid Precursor Protein SecretasesBrain-Derived Neurotrophic FactorCadherinsCdh2 protein, mouseMembrane ProteinsNtrk2 protein, mouseProtein-Tyrosine KinasesReceptor, trkBADAM10BDNFHuntingtinSynaptic dysfunctions

Identifiers

PMID39112663
PMCPMC11335257

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.